PriceTargets.com logo

Tarsus Pharmaceuticals - TARS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $54.20
  • Forecasted Upside: 2.44%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$52.91 As of 12/20/2024 06:31 PM ET
▲ +0.91 (1.75%)

This chart shows the closing price for TARS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tarsus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TARS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TARS

Analyst Price Target is $54.20
▲ +2.44% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Tarsus Pharmaceuticals in the last 3 months. The average price target is $54.20, with a high forecast of $65.00 and a low forecast of $41.00. The average price target represents a 2.44% upside from the last price of $52.91.

This chart shows the closing price for TARS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Tarsus Pharmaceuticals. This rating has held steady since August 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$36.00 ➝ $41.00
11/14/2024OppenheimerBoost TargetOutperform ➝ Outperform$63.00 ➝ $65.00
8/30/2024William BlairUpgradeStrong-Buy
8/9/2024OppenheimerReiterated RatingOutperform ➝ Outperform$61.00 ➝ $63.00
5/13/2024HC WainwrightBoost TargetBuy ➝ Buy$57.00 ➝ $61.00
5/10/2024BarclaysBoost TargetOverweight ➝ Overweight$50.00 ➝ $60.00
5/9/2024OppenheimerBoost TargetOutperform ➝ Outperform$59.00 ➝ $61.00
3/6/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$30.00 ➝ $44.00
2/29/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$19.00 ➝ $30.00
2/28/2024HC WainwrightBoost TargetBuy ➝ Buy$50.00 ➝ $57.00
2/28/2024BarclaysBoost TargetOverweight ➝ Overweight$40.00 ➝ $50.00
2/28/2024OppenheimerReiterated RatingOutperform ➝ Outperform$55.00 ➝ $59.00
12/26/2023Lifesci CapitalReiterated RatingOutperform
11/20/2023The Goldman Sachs GroupInitiated CoverageNeutral$19.00
11/10/2023HC WainwrightBoost TargetBuy ➝ Buy$42.00 ➝ $50.00
9/11/2023GuggenheimBoost TargetBuy ➝ Buy$46.00 ➝ $49.00
8/14/2023GuggenheimReiterated RatingBuy ➝ Buy$46.00
8/11/2023HC WainwrightLower TargetBuy ➝ Buy$50.00 ➝ $42.00
7/26/2023Bank of AmericaBoost Target$42.00 ➝ $54.00
7/26/2023HC WainwrightBoost TargetBuy$44.00 ➝ $50.00
7/18/2023William BlairInitiated CoverageOutperform$44.00
6/26/2023HC WainwrightBoost Target$40.00 ➝ $44.00
6/16/2023GuggenheimBoost Target$40.00 ➝ $42.00
5/18/2023GuggenheimInitiated CoverageBuy
3/15/2023HC WainwrightReiterated RatingBuy$40.00
11/10/2022OppenheimerLower Target$66.00 ➝ $43.00
8/1/2022BarclaysInitiated CoverageOverweight$40.00
5/3/2022HC WainwrightReiterated RatingBuy$40.00
5/2/2022OppenheimerBoost Target$55.00 ➝ $66.00
3/17/2022HC WainwrightReiterated RatingBuy$40.00
12/21/2021HC WainwrightInitiated CoverageBuy$40.00
11/22/2021OppenheimerInitiated CoverageOutperform$55.00
10/7/2021Raymond JamesBoost TargetStrong-Buy$50.00 ➝ $65.00
6/29/2021Raymond JamesBoost TargetStrong-Buy$39.00 ➝ $50.00
6/22/2021Jefferies Financial GroupBoost TargetBuy$35.00 ➝ $45.00
6/17/2021Raymond JamesReiterated RatingBuy
11/10/2020Lifesci CapitalReiterated RatingOutperform
11/10/2020Raymond JamesInitiated CoverageStrong-Buy$39.00
11/10/2020Jefferies Financial GroupInitiated CoverageBuy$35.00
11/10/2020LADENBURG THALM/SH SHInitiated CoverageBuy$42.00
11/10/2020Bank of AmericaInitiated CoverageBuy$33.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.19 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 9 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 9 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 12 very positive mentions
  • 23 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 13 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 13 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Tarsus Pharmaceuticals logo
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $52.91
Low: $50.20
High: $53.62

50 Day Range

MA: $46.51
Low: $36.45
High: $53.26

52 Week Range

Now: $52.91
Low: $18.99
High: $56.77

Volume

741,534 shs

Average Volume

712,735 shs

Market Capitalization

$2.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Tarsus Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Tarsus Pharmaceuticals in the last twelve months: Barclays PLC, HC Wainwright, Jefferies Financial Group Inc., Lifesci Capital, Oppenheimer Holdings Inc., The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for TARS.

What is the current price target for Tarsus Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Tarsus Pharmaceuticals in the last year. Their average twelve-month price target is $54.20, suggesting a possible upside of 2.4%. Oppenheimer Holdings Inc. has the highest price target set, predicting TARS will reach $65.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $41.00 for Tarsus Pharmaceuticals in the next year.
View the latest price targets for TARS.

What is the current consensus analyst rating for Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals currently has 1 hold rating, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TARS will outperform the market and that investors should add to their positions of Tarsus Pharmaceuticals.
View the latest ratings for TARS.

What other companies compete with Tarsus Pharmaceuticals?

Other companies that are similar to Tarsus Pharmaceuticals include Revolution Medicines, Lantheus, Nuvalent, Legend Biotech and Blueprint Medicines. Learn More about companies similar to Tarsus Pharmaceuticals.

How do I contact Tarsus Pharmaceuticals' investor relations team?

The company's listed phone number is 949-409-9820 and its investor relations email address is [email protected]. The official website for Tarsus Pharmaceuticals is www.tarsusrx.com. Learn More about contacing Tarsus Pharmaceuticals investor relations.